J&J pharma leader to retire; Krystal slumps on gene therapy miss
Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.
biopharma_dive · 10d ago
French gene therapy biotech gets €33M to follow Krystal's blueprint
A small French-US biotech has gathered more funds to see if it can follow in the footsteps of Krystal Biotech in the HSV-based gene therapy field, but in a different therapeutic area. Cyllene Thera…
endpoints · 1mo ago

Data sources

SEC EDGAR

last refreshed 1m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

PUBLIC COMPANY

save

$KRYSKrystal Biotech, Inc.

$KRYS332.27+1.20%

Pittsburgh, PA, USupdated 1h ago

Website SEC EDGAR Yahoo Finance

community read0 votes

pipeline

marketed

phase 3

catalysts ytd

approvals ytd

recalls ytd

Pipeline(5)

pipeline depth5 products

2Phase 12Phase 21Marketed

Marketed

beremagene geperpavec

Dystrophic Epidermolysis Bullosa

Neurotrophic Keratitis

Alpha-1 Antitrypsin Deficiency (A1AD)

Upcoming

Krystal Biotech, Inc. earnings

Krystal Biotech, Inc.

→

Recent(90d)

nothing in the last 90 days

view all catalysts →

Active trials

EP1A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Diseaserecruitingn=7
phase3A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosarecruitingn=16
phase2A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitisrecruitingn=60
phase2A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungsrecruitingn=250
phase1A Study Assessing KB407 for the Treatment of Cystic Fibrosisrecruitingn=12
phase1A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiencyrecruitingn=15
—A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)recruitingn=40
phase2A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumorsrecruitingn=240

more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

Mar 4, 26SELLKrishnan Krish S· President and CEO8,798 sh @ $264.85−$2.33M↗
Mar 4, 26SELLKrishnan Suma· President, R&D6,000 sh @ $265.16−$1.59M↗
Mar 4, 26SELLKrishnan Suma· President, R&D4,852 sh @ $264.64−$1.28M↗
Mar 4, 26SELLKrishnan Suma· President, R&D3,667 sh @ $260.37−$955K↗
Mar 4, 26SELLKrishnan Krish S· President and CEO3,128 sh @ $260.49−$815K↗
Mar 4, 26SELLKrishnan Krish S· President and CEO2,962 sh @ $261.41−$774K↗
Mar 4, 26SELLKrishnan Suma· President, R&D2,931 sh @ $261.41−$766K↗
Mar 4, 26SELLKrishnan Krish S· President and CEO2,439 sh @ $265.59−$648K↗
Mar 4, 26SELLKrishnan Krish S· President and CEO2,380 sh @ $262.44−$625K↗
Mar 4, 26SELLKrishnan Suma· President, R&D2,248 sh @ $263.58−$593K↗
Mar 4, 26SELLKrishnan Krish S· President and CEO2,043 sh @ $263.70−$539K↗
Mar 4, 26SELLKrishnan Suma· President, R&D1,938 sh @ $262.35−$508K↗
Mar 4, 26SELLKrishnan Suma· President, R&D1,700 sh @ $266.42−$453K↗
Mar 4, 26SELLKrishnan Krish S· President and CEO1,377 sh @ $259.87−$358K↗
Mar 4, 26SELLKrishnan Krish S· President and CEO920 sh @ $266.56−$245K↗
Mar 4, 26SELLKrishnan Suma· President, R&D668 sh @ $259.61−$173K↗
Mar 4, 26SELLKrishnan Suma· President, R&D589 sh @ $258.54−$152K↗
Mar 4, 26SELLKrishnan Krish S· President and CEO483 sh @ $257.31−$124K↗
Mar 4, 26SELLKrishnan Krish S· President and CEO470 sh @ $258.38−$121K↗
Mar 4, 26SELLKrishnan Suma· President, R&D407 sh @ $257.32−$105K↗

🐶 Hiring Signal

next earnings Nov 2, 2026

No open roles indexed yet — view Krystal Biotech, Inc. jobs →

News

J&J pharma leader to retire; Krystal slumps on gene therapy miss
Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.
biopharma_dive · 10d ago
French gene therapy biotech gets €33M to follow Krystal's blueprint
A small French-US biotech has gathered more funds to see if it can follow in the footsteps of Krystal Biotech in the HSV-based gene therapy field, but in a different therapeutic area. Cyllene Thera…
endpoints · 1mo ago

Data sources

SEC EDGAR

last refreshed 1m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

$KRYSKrystal Biotech, Inc.

Pipeline(5)

Upcoming

Recent(90d)

Active trials

Insider activity

open-market buys + sells

News

Report a data issue

comments(0)

$KRYSKrystal Biotech, Inc.

Pipeline(5)

Upcoming

Recent(90d)

Active trials

Insider activity

open-market buys + sells

News

Report a data issue

comments(0)

$KRYSKrystal Biotech, Inc.

Pipeline(5)

📅 Upcoming

🕒 Recent(90d)

Active trials

Insider activity

open-market buys + sells

News

comments(0)

$KRYSKrystal Biotech, Inc.

Pipeline(5)

📅 Upcoming

🕒 Recent(90d)

Active trials

Insider activity

open-market buys + sells

News

comments(0)

Upcoming

Recent(90d)

Upcoming

Recent(90d)